{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:40:17Z","timestamp":1733056817691,"version":"3.30.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3499,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1002\/hep.21085","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T02:46:42Z","timestamp":1138330002000},"page":"221-224","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Acute hepatitis C: In search of the optimal approach to cure"],"prefix":"10.1097","volume":"43","author":[{"given":"Antonio","family":"Crax\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Licata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20241201","doi-asserted-by":"crossref","first-page":"590598","DOI":"10.1016\/j.jhep.2005.04.007","article-title":"East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germanya 25year multicenter study.","volume":"43","author":"Wiese","year":"2005","journal-title":"J Hepatol"},{"key":"R2-3-20241201","first-page":"8088","article-title":"Acute hepatitis C: high rate of both spontaneous and treatmentinduced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"R4-3-20241201","first-page":"339344","article-title":"The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.","volume":"288","author":"Farci","year":"14","journal-title":"Science"},{"key":"R5-3-20241201","doi-asserted-by":"crossref","first-page":"323328","DOI":"10.1016\/j.jhep.2004.11.018","article-title":"Swiss Association for the Study of the Liver (SASL 18). Barriers to interferonalpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.","volume":"42","author":"Broers","year":"2005","journal-title":"J Hepatol"},{"key":"R6-3-20241201","doi-asserted-by":"crossref","first-page":"505509","DOI":"10.1002\/jmv.2064","article-title":"Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C.","volume":"65","author":"Hwang","year":"2001","journal-title":"J Med Virol"},{"key":"R7-3-20241201","doi-asserted-by":"crossref","first-page":"387391","DOI":"10.1002\/jmv.20103","article-title":"High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.","volume":"73","author":"Lehmann","year":"2004","journal-title":"J Med Virol"},{"key":"R8-3-20241201","doi-asserted-by":"crossref","first-page":"26092617","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.","volume":"352","author":"Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"R9-3-20241201","doi-asserted-by":"crossref","first-page":"522527","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferonalpha2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.","volume":"129","author":"von Wagner","year":"2005","journal-title":"Gastroenterology"},{"key":"R10-3-20241201","doi-asserted-by":"crossref","first-page":"646651","DOI":"10.1016\/j.jhep.2004.12.027","article-title":"Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM antiHCV titres.","volume":"42","author":"Sagnelli","year":"2005","journal-title":"J Hepatol"},{"key":"R11-3-20241201","first-page":"6064","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.","volume":"37","author":"Hofer","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R12-3-20241201","doi-asserted-by":"crossref","first-page":"14521457","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa2b.","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"R13-3-20241201","doi-asserted-by":"crossref","first-page":"10561062","DOI":"10.1016\/S0168-8278(03)00461-6","article-title":"When and how to treat acute hepatitis C?","volume":"39","author":"Licata","year":"2003","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R15-3-20241201","first-page":"S1S235","article-title":"September 14-16, 2002. Geneva, Switzerland.","volume":"39","year":"2003","journal-title":"J Hepatol"},{"key":"R16-3-20241201","doi-asserted-by":"crossref","first-page":"293296","DOI":"10.1016\/j.jhep.2004.12.012","article-title":"Treatment of acute hepatitis C infection: more pieces of the puzzle?","volume":"42","author":"Zekry","year":"2005","journal-title":"J Hepatol"},{"key":"R17-3-20241201","first-page":"250256","article-title":"Early monotherapy with peginterferon alfa2b for acute hepatitis C infection: The HEPNET AcuteHCVII Study.","volume":"43","author":"Wedemeyer","year":"2006","journal-title":"HEPATOLOGY"},{"key":"RU18-3-20241201","doi-asserted-by":"crossref","first-page":"395403","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, doubleblind trial comparing pegylated interferon alfa2b to interferon alfa2b as initial treatment for chronic hepatitis C.","volume":"34","author":"Lindsay","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R20-3-20241201","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1097\/01.qai.0000174930.64145.a9","article-title":"Transmission of hepatitis C virus among HIVpositive homosexual men and response to a 24week course of pegylated interferon and ribavirin.","volume":"40","author":"Gilleece","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-3-20241201","doi-asserted-by":"crossref","first-page":"12011203","DOI":"10.1002\/hep.20221","article-title":"Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C.","volume":"39","author":"Wedemeyer","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R22-3-20241201","doi-asserted-by":"crossref","first-page":"104113","DOI":"10.1016\/S1590-8658(03)00007-0","article-title":"Natural course of acute hepatitis C: a longterm prospective study.","volume":"35","author":"Santantonio","year":"2003","journal-title":"Dig Liver Dis"},{"key":"R23-3-20241201","doi-asserted-by":"crossref","first-page":"12139","DOI":"10.1002\/hep.20196","article-title":"Shortterm interferonalfa therapy for acute hepatitis C: a randomized controlled trial.","volume":"39","author":"Nomura","year":"2004","journal-title":"HEPATOLOGY"},{"issue":"Suppl 1","key":"R24-3-20241201","first-page":"189192","article-title":"Treatment of acute hepatitis C virus infection.","volume":"31","author":"Vogel","year":"1999","journal-title":"J Hepatol"},{"key":"R25-3-20241201","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1365-2036.2004.02023.x","article-title":"Treatment of acute hepatitis C with interferon alpha2b: early initiation of treatment is the most effective predictive factor of sustained viral response.","volume":"20","author":"Delwaide","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-3-20241201","doi-asserted-by":"crossref","first-page":"202211","DOI":"10.1097\/00002371-200305000-00004","article-title":"Biologic activity of polyethylene glycol12000interferonalpha2b compared with interferonalpha2b: gene modulatory and antigrowth effects in tumor cells.","volume":"26","author":"Vyas","year":"2003","journal-title":"J Immunother"},{"key":"R27-3-20241201","doi-asserted-by":"crossref","first-page":"329333","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24week course of PEGinterferon alpha2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"R29-3-20241201","first-page":"294299","article-title":"Early treatment of acute hepatitis C with interferon alpha2b or interferon alpha2b plus ribavirin: study of sixteen patients.","volume":"27","author":"Rocca","year":"2003","journal-title":"Gastroenterol Clin Biol"},{"key":"R30-3-20241201","doi-asserted-by":"crossref","first-page":"W91W92","DOI":"10.7326\/0003-4819-141-6-200409210-00031-w1","article-title":"Waitandsee: an alternative approach to managing acute hepatitis C with highdose interferonalpha monotherapy.","volume":"141","author":"Pimstone","year":"2004","journal-title":"Ann Intern Med"},{"key":"R31-3-20241201","doi-asserted-by":"crossref","first-page":"98107","DOI":"10.1002\/hep.20291","article-title":"Longterm followup after successful interferon therapy of acute hepatitis C.","volume":"40","author":"Wiegand","year":"2004","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21085","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200602000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:03:01Z","timestamp":1733054581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200602000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21085","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}